Troy– Author –
-
Imec and EV Group Set New World Record for 3D Chip Stacking Precision with Sub-40nm Wafer Bond Overlay
PR Newswire ベルギー Overview Imec and EV Group have achieved a world-record post-bond overlay accuracy of less than 40 nanometers across a 300mm wafer for 200nm pitch hybrid bonding, a crucial advancement for next-generation 3D ICs. Dem... -
TSMC CoWoS Capacity Becomes Major AI Chip Growth Bottleneck: Ramping to 120K Wafers/Month by late 2026 Still Falls Short of Demand
backplane Taiwan Overview TSMC's CoWoS packaging capacity is identified as the most critical bottleneck hindering AI chip evolution. While TSMC plans to quadruple its CoWoS production capacity from approximately 35,000 wafers/month in la... -
KLA’s Advanced Packaging Business Soars, Projecting Over $1.3B Revenue in FY2026 Driven by AI Inspection Demand
Bitget USA Overview KLA Corporation, a global leader in semiconductor process control and yield management, is experiencing rapid growth in its advanced packaging business, driven by the increasing complexity of AI chips. Revenue from th... -
ASMPT Establishes Advanced Packaging Technology Advisory Council to Accelerate AI-Era Innovation
ASMPT Singapore Overview ASMPT has established an Advanced Packaging Technology Advisory Council (TAC) to address the growing importance of advanced packaging for next-generation computing and AI components. The TAC will focus on a broad... -
Aurobindo Pharma Inaugurates ₹10 Billion (USD 120M) TheraNym Biologics CDMO Plant in India, Expanding Capacity by 25,000L
Sahi India Overview Aurobindo Pharma announced the inauguration of its state-of-the-art ₹10 billion (approx. USD 120 million) TheraNym biologics CDMO facility in Hyderabad, India. This plant adds 25,000 liters of mammalian cell culture c... -
FDA Grants Breakthrough Therapy Designation to Merck’s Investigational KRAS G12C Inhibitor Calderasib (MK-1084) in Combination with KEYTRUDA for Metastatic NSCLC
BioSpace USA Overview Merck announced that its investigational oral KRAS G12C inhibitor, calderasib (MK-1084), in combination with KEYTRUDA® (pembrolizumab), received FDA Breakthrough Therapy Designation for newly diagnosed metastatic KR... -
Mount Sinai Scientists Discover Hidden Drug-Binding Pocket in Cancer Protein PKMYT1, Highlighting AI Drug Discovery’s Capabilities and Limitations
Mount Sinai - New York USA Overview Mount Sinai scientists discovered a previously overlooked drug-binding pocket in the cancer-related protein PKMYT1. This finding, while highlighting AI drug discovery's capabilities and limitations, op... -
Biogen’s Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (SMA)
PMLiVE USA Overview Biogen's investigational antisense oligonucleotide (ASO), salanersen, has received FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy (SMA). This designation is based on early clinical data showing impro... -
Janssen’s TECVAYLI® (teclistamab) Achieves Superior Progression-Free and Overall Survival Versus Standard of Care as Early as First Relapse in Multiple Myeloma
Janssen USA Overview New data from the MajesTEC-9 study revealed that TECVAYLI® (teclistamab) demonstrated superior progression-free and overall survival compared to standard of care in patients with relapsed/refractory multiple myeloma ... -
CicadaBio Presents Novel Preclinical Data for CC-18, a GLP-1/ActRII Fusion Protein Designed for Muscle-Preserving Weight Loss, at ADA 2026
Business Wire USA Overview CicadaBio orally presented novel preclinical data for CC-18, a first-in-class GLP-1/ActRII fusion protein designed for muscle-preserving weight loss, at the American Diabetes Association (ADA) 2026 Scientific S...
